Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?

被引：2
|
作者：
Franses, Joseph W. [1 ,2 ,3 ]
Hong, Theodore S. [1 ,2 ]
Zhu, Andrew X. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02114 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2019年 / 4卷 / 08期
关键词：
TRACT CANCER; PEMBROLIZUMAB;
D O I：
10.1016/S2468-1253(19)30148-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：575 / 577
页数：4
相关论文
共 50 条
  • [31] A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01
    Sahai, Vaibhav
    Griffith, Kent A.
    Beg, Muhammad S.
    Shaib, Walid L.
    Mahalingam, Devalingam
    Zhen, David B.
    Deming, Dustin A.
    Zalupski, Mark M.
    CANCER, 2022, 128 (19) : 3523 - 3530
  • [32] Gemcitabine in advanced biliary tract cancers
    Pasetto, Lara Maria
    Andrea, Mario Rosario D'
    Falci, Cristina
    Monfardini, Silvio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 61 (03) : 230 - 242
  • [33] Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis
    Yang, Rui
    Wang, Bing
    Chen, Yong-jun
    Li, Hong-bo
    Hu, Jun-bo
    Zou, Sheng-quan
    ANTI-CANCER DRUGS, 2013, 24 (08) : 871 - 877
  • [34] Evaluation of chemotherapy with cisplatin plus gemcitabine after failure of gemcitabine alone for unresectable or recurrent biliary tract cancer.
    Kameda, Ryo
    Ando, Tomoko
    Kobayashi, Satoshi
    Ueno, Makoto
    Ohkawa, Shinichi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] COST-EFFECTIVENESS OF GEMCITABINE PLUS CISPLATIN VERSUS GEMCITABINE ALONE FOR TREATMENT OF ADVANCED BILIARY TRACT CANCER IN JAPAN
    Arakawa, I
    Uemura, S.
    Murasawa, H.
    Inoue, T.
    VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [36] A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
    Ikeda, Masafumi
    Ueno, Makoto
    Morizane, Chigusa
    Kobayashi, Satoshi
    Ohno, Izumi
    Kondo, Shunsuke
    Okano, Naohiro
    Kimura, Keisuke
    Asada, Suguru
    Namba, Yoshinobu
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [37] Gemcitabine plus cisplatin in breast cancer
    Nagourney, RA
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 28 - 33
  • [38] Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study
    Woo, Sang Myung
    Lee, Woo Jin
    Kim, Ji Hun
    Kim, Dong Hwan
    Han, Sung-Sik
    Park, Sang-Jae
    Kim, Tae Hyun
    Lee, Ju Hee
    Koh, Young Hwan
    Hong, Eun Kyung
    CHEMOTHERAPY, 2013, 59 (03) : 232 - 238
  • [39] ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC)
    Goldstein, D.
    Shannon, J.
    Brown, C.
    Tebbutt, N.
    Ackland, S.
    Van Hazel, G.
    Abdi, E.
    Jefford, M.
    Gainford, M. C.
    Adams, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers
    Ogul, Ali
    Kidi, Mehmet Mutlu
    Buyuksimsek, Mahmut
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (01) : 294 - 299
12345